Precigen CFO Sells $1.1 Million in Shares Amid Stock Surge and FDA Orphan Drug Designation for Papzimeos
核心洞察
Precigen CFO Harry Thomasian Jr. sold 200,000 shares for approximately $1.1 million under a pre-arranged Rule 10b5-1 trading plan between June 29 and July 1, 2026.
The sale reduced Thomasian's direct holdings by 36.07%, with 354,535 shares remaining, and was executed at a weighted average price of $5.57 per share.
Precigen shares reached a multi-year high of $6.04 on June 29, driven by strong Q1 revenue of $23.3 million, up from $1.3 million in the prior year.
On July 1, 2026, Precigen (PGEN) Chief Financial Officer Harry Thomasian Jr. reported the sale of 200,000 shares of common stock in multiple open-market transactions between June 29 and July 1, 2026, according to an SEC Form 4 filing. The transaction, valued at approximately $1.1 million, reduced Thomasian's direct holdings by 36.07%, leaving him with 354,535 shares directly held.
The sale occurred as Precigen shares reached a multi-year high of $6.04 on June 29, with the company's one-year total return standing at 254.72% as of the transaction date. Shares were sold at a weighted average price of approximately $5.57 per share, representing an execution roughly 6% above the July 1, 2026 closing price of $5.25.
A Pre-Arranged Trading Plan
The sizable disposition — representing over one-third of Thomasian's remaining direct holdings — was executed under a pre-arranged Rule 10b5-1 trading plan. Such plans allow corporate insiders to sell shares at predetermined times, thereby avoiding concerns about trading on material non-public information. Consequently, the sales are not necessarily a red flag for investors.
The trade follows a prior disposition of 41,884 shares in May 2026, which had brought Thomasian's direct holdings down to 554,535 shares before this most recent filing. No indirect shares or derivative securities were involved in either transaction; all shares sold originated from direct ownership, and no options were listed in the filing.
Strong Financial Performance and Regulatory Milestone
Precigen's stock surge has been fueled by robust first-quarter business performance. The company reported Q1 revenue of $23.3 million, a substantial increase over the prior year's $1.3 million.
Adding to the momentum, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to the company's Papzimeos (搜索) treatment for adults with recurrent respiratory papillomatosis (搜索). This designation provides Precigen with market exclusivity through August 2032 as the only FDA-approved therapy for this indication.
Company Profile
Precigen is a biotechnology company specializing in gene and cellular therapy platforms designed to address unmet medical needs in oncology and regenerative medicine. The company's proprietary platforms include UltraVector, UltraCAR-T, and ActoBiotics. It generates revenue through product development, licensing, and strategic collaborations with biopharmaceutical and biotechnology partners, targeting healthcare organizations, research institutions, and biotechnology companies seeking advanced gene therapy, immunotherapy, and regenerative medicine solutions.